province was 24 per 100,000 population among children aged 0 to 4 years for the period of [1985] [1986] [1987] . 6 The high prevalence of HIV and TB in this region led to a rise in TBM. 7, 8 In the Western Cape province, TBM was the leading cause of meningitis among children below 13 years of age. 7 Diagnosis of TBM is complicated because of its non specific clinical presentation which may be acute, sub acute or chronic. It may be febrile or afebrile. The signs and symptoms of stage 1 TBM disease are non specific and relate more to primary lung infection than neurological disease. 5 TBM mainly affects young children with the mean age ranging between 23 and 49 months. 9, 10, 11 Diagnosis requires a high index of suspicion from the clinician. The Mantoux test is positive in only 30 to 50% and chest X-ray is normal in 20-50% of cases. 10, 11 Although radiological tests such as brain Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) are helpful, they may be normal in early stages and are not widely available in resource limited settings. Lumbar cerebrospinal fluid (CSF) is the most valuable test. The CSF proteins are elevated and may be markedly raised to 0.4 g/L Presentation and outcome of tuberculous meningitis among children: experiences from a tertiary children's hospital to 5.0g/L secondary to hydrocephalus and spinal block. However, ventricular CSF may record normal chemistry and cells if drawn from a site proximal to the inflammation and obstruction. Leukocytes in CSF are increased to 10-500 cells/mm 3 , with majority having lymphocyte predominance. However, neutrophils may predominate initially which can confuse the picture. The gold standard in diagnosis of TBM is positive culture of Mycobacteria tuberculosis from CSF which has both a long turn around time and a low smear and mycobacteria culture positive rate except if 10 to 20ml of CSF are supplied to the laboratory. 12 Newer tests like the GeneXpert with a quick turn around time have been found to have a high sensitivity on sputum even in children. 13 However, studies show a reduced sensitivity of GeneXpert in CSF compared to sputum. 14 Other tests that would support TBM diagnosis like sputum or gastric aspirates also have low culture yields. 5 To standardize diagnosis, a consensus case definition using clinical presentation, laboratory and radiological findings was made to guide clinicians and researchers.
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Outcome of TBM is generally poor with mortality among children ranging between 13-69%. 9, 16, 17 Younger age, tonic posturing, papilloedema, focal neurological deficit and stage at presentation were found to affect the prognosis. 16, 17 Red Cross War memorial Children's Hospital (RCWMCH) is a high TB and HIV burden setting with the prevalence of HIV and TB of 27.6% and 16.7% respectively among admitted patients on general paediatric wards. 18 With this high prevalence, there was a need to document the diagnosis and treatment outcome of TBM in this hospital. We set out to describe our experiences in the presentation, diagnostic rigor, treatment and outcome of TBM at discharge from RCWMCH in the year 2009. /L, protein >0.45 g/L and glucose <2.2 mmol/L), plus 3) one or more of the following i) chest radiograph findings consistent with pulmonary TB, ii) an extra-meningeal specimen positive for AFB, iii) other evidence of extra-meningeal TB (e.g. abdominal ultrasound features) or iv) brain computed tomography (CT) evidence of TBM including one or more of the following: basal meningeal enhancement, hydrocephalus or infarctions. Possible TBM was diagnosed when: 1) a patient presented with clinical features of meningitis and either 2) four or more of the following were present i) a history of TB ii) a predominance of CSF lymphocytes (>50%), iii) illness duration of more than five days iv) CSF glucose <2.2 mmol/L, v) altered consciousness, vi) clear or yellow CSF with protein>1 g/L, vii) focal neurological signs, or 3) 'markedly abnormal' CSF (excluding isolated hypoglycemia) with evidence of TB elsewhere.
Methodology
For children who were transferred to other hospitals in Cape Town to complete their treatment, those hospitals were visited and their treatment outcomes at discharge recorded. The outcome of treatment variables were improvement with / without neurological sequelae, or death. Poor outcome was defined as death or neurological sequelae at discharge. The neurological sequelae were obtained from the doctors' notes and it included physical neurological sequelae. The Mantoux skin test is regarded as reactive as defined by guidelines of the World Health Organization: in high risk children (including HIV-infected children and severely malnourished children), >5 mm of induration, and in all other children (whether they have received a BCG vaccination or not), >10 mm of induration. 19 TBM staging was undertaken using the modified criteria of the British Medical Research Council: 20 in which TBM Stage I is defined as (Glasgow Coma Scale (GCS) 15 with no focal neurologic signs), TBM stage II is (GCS 11-14 or GCS of 15 with focal neurologic deficit) and TBM stage III is (GCS <11).
Statistical Analysis
Data was entered anonymously into an excel spreadsheet. To assess the accuracy of the data entered, a random sample of the original forms was compared with a computer print-out. Data was analyzed using STATA statistical package (StataCorp, Version 11). Descriptive analysis using medians with inter-quartile ranges (IQR) are described for continuous variables that are not normally distributed while means and standard deviations (SD) are used for normally distributed data. For categorical variables, proportions are depicted as percentages of cases for which data is available. Data were tested for normality and the appropriate statistical test was used to test for strength of association.
Results
Of 22,943 children admitted to RCWMCH during the study period, we identified 40 children newly diagnosed with TBM; an incidence rate of 1.7 per 1000 admissions. The median age was 32 months (IQR 9-78.5) ranging from 6 weeks to 12 years. The male: female ratio was 1:1. Clinical features present at admission are summarized in table 1. Common features included fever, vomiting, meningism, neurological deficits, altered level of consciousness and failure to thrive. Although 25/30 (83%) had a history of fever, 14/38 (37%) had a temperature of 37. According to the consensus case definition of TBM 12 , 6 (15%) had definitive TBM, 17 (42%), probable TBM and 18 (44%) possible TBM. Thirty-five patients (87%) were screened for HIV, of whom only 3 (10%) were infected. No patients were receiving antiretroviral therapy (ART) at the time of TBM diagnosis. In addition, two were HIV exposed but their HIV DNA/PCR test was negative. Only 20/40 had available records on immunization and they all had received BCG vaccination. Of the 30 who had data on chest X-ray findings, abnormal findings were present in 24 (71%). Seventeen (57%) had findings suggestive of TB which included 5 (29%) with hilar or mediastinal lymphadenopathy, 4 (24%) with miliary picture, 4 (24%) with hilar adenopathy and reticulonodular infiltrates, 2 (12%) with lobar infiltrates, 1 (6%) with consolidation and perihilar infiltrates and 1 (6%) with consolidation and fine nodular opacities like miliary. Other abnormal chest X-ray findings included 3 with isolated right upper lobe consolidation, 3 with peri-hilar and hilar infiltrates and pneumonia and 1 with bronco pneumonic picture. Neuroimaging tests revealed that 33/36 (92%) had an abnormality on CT or MRI as shown on table 3. The commonest finding was basal meningeal enhancement which was present in 50% but 25/33 (76%) had multiple abnormalities; 12 had 2 abnormalities, 9 had 3 abnormalities and 4 had 4 abnormalities.
Management and Outcome:
All the children were treated with oral rifampicin, isoniazid, pyrazinamide and ethionamide which is the standard treatment in the country. 21 They all received glucocorticosteroids; 36 (90%) received Prednisolone and 4/40 (10%) received Dexamethazone. Mannitol was administered to 6/40 (15%). TB treatment was started on day 1 of admission in 25/37(67.5%), day 2 in 5/37 (13.5%) and day 3 in 7/37 (19%). Three of the patients had no clear records about the date of initiation of TB treatment. Surgery was performed on 10/40 (25%) -an extraventricular drain (EVD) alone was inserted in 3 children, 6 children received a ventriculoperitoneal (VP) shunt alone and 1 child had both EVD and VP shunt. Six (15%) children with communicating hydrocephalus received serial lumbar punctures to reverse raised intracranial pressure. All 6 children had poor outcome. Children with poor outcome of death and neurological sequelae had a statistically longer hospital stay with a median of 30 days, IQR 16-40 days while those with good outcome had a median of 5 days, IQR 2-17 days (Mann Whitney p<0.001). From RCWMCH, 2 went home, 2 died and 36 were referred to another hospital to complete their treatment. Of this latter group, 21 were admitted to the local TB hospital, Brooklyn Chest Hospital and 15 admitted to general hospitals in Cape
The outcome of 4 children could not be established because they were transferred to other hospitals too early and we did not find the data on outcome at discharge.
The trends noted with poor outcome were having surgery; (8 versus 1), serial LPs, (6 versus none), acetazolamine use (7 versus none) and longer mean hospital stay. There was a strong association between poor outcome (death and neurological sequale) and TBM stage 3 on admission, Fischer's exact test p<0.01. There was no association found between poor outcome and other presentations on admission. These included HIV status, CSF white cell count, age, CSF chemistry (protein and glucose), microscopy and culture. The neurological sequelae experienced by the 18 children included hydrocephalus, (11), motor deficits (11), cranial nerve palsies (9), deafness (2), epilepsy (1), cortical blindness (1). Twelve of them suffered multiple sequelae.
Discussion
TBM is a severe disease whose initial presentation in children is like other common childhood illnesses resulting in late diagnosis. Although it is usually associated with poor outcome, our study found better treatment outcome and several lessons that can be drawn and applied. We found a mean age of 48 months and only 11 were infants under 1 year. This is comparable to what several studies indicate that TBM mainly affects young children with the mean age ranging between 23 and 49 months. [9] [10] [11] All the 20 children with immunization records had BCG vaccine which is not surprising because although BCG is protective against TBM, studies show that those who get TBM after vaccination have a better treatment outcome. 22 RCWMCH has a high HIV prevalence of 27.6% on general paediatric wards but it was surprisingly low at 9.7% among those with TBM. Previous studies showed that HIV is a risk factor for central nervous system TB. 3, 5, 7, 8, 23 However, Gijs et al also found a low HIV prevalence of 3.8% among children with TBM in Western cape province. 9 This could be explained by the high burden of TB in the region such that children are infected regardless of their HIV status.
We found that TBM in these children presented mainly with non specific common childhood diseases but the data on duration was generally deficient. Of the 19 who had duration of fever, all were affected for less than 10 days. Cough was acute in 8/15 (53%) of children. Several studies have similar findings of short duration of symptoms. 5, [8] [9] [10] More severe symptoms like convulsions and impaired level of consciousness were present in 12/16 (75%)% and 23/32 (72%) respectively. These percentages seem high because many did not have records and it can be hypothesized that the ones without records most likely did not have the symptoms. Paradoxically, failure to thrive was present among 22/25 (88%) despite the short duration of symptoms in the majority. This is similar to Gitz et al's study. 9 We could not determine missed opportunities of early treatment because of the retrospective design. This has been described by other studies. 5, 9 Despite the difficulties of diagnosis of TBM, our study demonstrated that almost all had a diagnosis made by day 3 of admission. This is because of the high index of suspicion and also the hospital had access to quick laboratory and radiological tests which helped make a quick diagnosis and also start treatment early. Definite TBM was present in only 15% (Mycobacterium tuberculosis isolated from CSF).
15 TB culture positive rates in CSF were lower in this study because only one sample was used. Daniel et al found that culture positive rates can go up from 53% on the first specimen to 83% with the third specimen. Town. Table 4 summarizes the outcome at final hospital discharge. 9 Unfortunately, we did not grade the neurological sequelae due to the deficient data in our retrospective study. Outcome would also be different at the end of treatment compared to the time of hospital discharge when the neurological outcome is still evolving. The mortality in our study was 8% which is much lower than has been described in other studies where mortality ranges between 13% and 69% even in developed countries. [8] [9] [10] [25] [26] [27] [28] The better outcome in this study may be because all the 37 with records on date of starting antiTB treatment (ATT) had started treatment within 3 days of admission. Early initiation of treatment has been established as the main prognostic factor that predicts disease lethality and sequelae. [29] [30] In addition, only 9 had TBM stage III basing on the GCS although 23 had impaired level of consciousness at admission. Stage III is associated with worse outcome. 9, 16, 17 Availability of radiological tests like CT and MRI which were performed in 36/40 (90%) and were abnormal in 89% of cases further strengthened the diagnosis and then early treatment. Since TB prevalence is high in this region, TBM is always held in high suspicion and treatment was started early with good results.
In addition, the prevalence of HIV was low in the study. HIV was not associated with poor outcome probably because the numbers were very few. HIV co-infection has been associated with poor treatment outcome of TBM in children. 9 Like in other studies, we found that TBM stage III was associated with increased mortality. 9, 16, 17 Our study was not powered to look for associations but those who had surgery, serial LPs, acetazolamine use and longer mean hospital stay had poor outcome of death and neurological sequelae. Similarly, longer hospital stay has been associated with poor outcome. 31 Misra et al also found that hydrocephalus and shunt surgery were poor prognostic features. 17 The strength of this descriptive study is that we used a retrospective chart review to attain data on a disease known to have very poor outcome and found better outcome than other studies. Our findings suggest that it is possible to reduce mortality and to improve outcome from TBM with rigorous diagnostics and early treatment initiation.
Limitations of our study included the retrospective design in which data recording was not standardized and as such some information was missing. In addition, we used the neurological sequelae recorded by the doctors in the folders which had missing data and could not therefore grade it. Another limitation was with our entry point which was the hospital records department. Some TBM diagnoses may have been missed out just as we found that some codes were in error.
Conclusions
We found that TBM mainly presented with acute non specific symptoms but the rigorous diagnostics helped make a quick diagnosis and start early treatment. Outcome of treatment at discharge was good with less than 10% mortality and half with neurological sequelae at discharge from hospital. Poor outcome was associated with TBM stage III disease.
Recommendations
We recommend a prospective study on the same topic so that the sequelae can be well documented. Since the presentation of TBM is non specific, clinicians in high TB endemic regions should have a high index of suspicion among all children with or without HIV infection. On suspicion of TBM, TB treatment should be started in the first 2 days of admission to improve the outcome.
